Testing a potential biosimilar for multiple resected solid tumors
Treatments studied
Part of Cancer, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests whether a new drug, HLX17, works as well as the approved drug Keytruda® in people whose solid tumors (like lung cancer, melanoma, or kidney cancer) have been fully removed by surgery. The goal is to see if the new drug can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- Your body weight is between 110 and 187 pounds (50 to 85 kg) and your BMI is between 18 and 30.
- You have had surgery to completely remove one of these cancers: non-small cell lung cancer, melanoma, or kidney cancer (at intermediate-high or high risk of coming back).
- You are in good physical condition (able to do normal activities without help).
- You have not had prior treatment with Keytruda or similar immunotherapy drugs.
- You are willing to use effective birth control during the study and for 6 months after the last dose if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two cancer drugs (HLX43 and Serplulimab) for people with advanced solid tumors, especially those with a specific type of lung cancer (NSCLC) that has an EGFR mutation. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new combination of two drugs for people with advanced lung cancer that has worsened after previous treatments like chemotherapy or immunotherapy. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
This study tests if a new drug called HLX17 works as well as the approved drug Keytruda for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see which one better controls the cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.